Expert Ratings for Neurocrine Biosciences
Portfolio Pulse from Benzinga Insights
Neurocrine Biosciences (NASDAQ:NBIX) has received various analyst ratings in the last quarter, with 6 bullish, 3 somewhat bullish, and 7 indifferent. Over the past 3 months, 16 analysts have offered 12-month price targets for the company, with an average price target of $121.62, a 1.98% decrease from the previous average price target of $124.08.
June 30, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Neurocrine Biosciences has received mixed analyst ratings in the last quarter, with a decrease in the average price target.
The mixed analyst ratings indicate uncertainty about the company's performance. The decrease in the average price target could potentially impact the stock price, but it's not clear whether this will lead to a decrease or increase in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100